ArticleBMC nephrology2016
Vitamin D deficiency may predict a poorer outcome of IgA nephropathy.
Article in BMC nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Guideline
- Trial
- Beyond traditional roles: vitamin D and erythropoietin as immune modulators in kidney diseases.Clinical kidney journal · 2026Review
- Bidirectional Mendelian randomization analysis of the causal associations between serum vitamin D levels and multiple kidney diseases.Scientific reports · 2025Article
- Vitamin D and chronic kidney disease: mechanisms, clinical implications, and future perspectives.Frontiers in medicine · 2025Review
- Effect of time-weighted average 25(OH)D on the occurrence of major adverse kidney events in IgA nephropathy-from a 10-year population-based cohort study.Frontiers in nutrition · 2025Article
- Association of vitamin D status with disease severity and outcome in Indian patients with IgA nephropathy.BMC nephrology · 2023Article
- Vitamin D receptor gene polymorphisms in chronic kidney disease Egyptian children: effect on biochemical markers of bone mineral disorders.Pediatric endocrinology, diabetes, and metabolism · 2022Article
- Vitamin D and Glomerulonephritis.Medicina (Kaunas, Lithuania) · 2021Review
- Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management.Frontiers in immunology · 2020Review
- Association betweenPeerJ · 2019Article
- Maternal vitamin D deficiency increases the risk of adverse neonatal outcomes in the Chinese population: A prospective cohort study.PloS one · 2018Article
- The association between serum vitamin D levels and renal tubular dysfunction in a general population exposed to cadmium in China.PloS one · 2018Article
- Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases.Current medicinal chemistry · 2018Review
- Calcitriol Ameliorates AngiotensinII-Induced Renal Injury Partly via Upregulating A20.Inflammation · 2017Article
- Effect of Vitamin D and Tacrolimus Combination Therapy on IgA Nephropathy.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExperimental studies showed that 25-hydroxy-vitamin D [25(OH)D] deficiency (defined as 25-hydroxy-vitamin D < 15 ng/ml) has been associated with CKD progression. Patients with IgA nephropathy have an exceptionally high rate of severe 25(OH)D deficiency; however, it is not known whether this deficiency is a risk factor for progression of IgA nephropathy. We conducted this study to investigate the relationship between the plasma level of 25(OH)D and certain clinical parameters and renal histologic lesions in the patients with IgA nephropathy, and to evaluate whether the 25(OH)D level could be a good prognostic marker for IgA nephropathy progression.
methodsA total of 105 patients with biopsy-proven IgA nephropathy were enrolled between 2012 and 2015. The circulating concentration of 25(OH)D was determined using serum samples collected at the time of biopsy. The primary clinical endpoint was the decline of estimated glomerular filtration rate (eGFR; a 30 % or more decline compared to the baseline).
resultsMean eGFR decreased and proteinuria worsened proportionally as circulating 25(OH)D decreased (P < 0.05). The 25(OH)D deficiency was correlated with a higher tubulointerstitial score by the Oxford classification (P = 0.008). The risk for reaching the primary endpoint was significantly higher in the patients with a 25(OH)D deficiency compared to those with a higher level of 25(OH)D (P = 0.001). As evaluated using the Cox proportional hazards model, 25(OH)D deficiency was found to be an independent risk factor for renal progression [HR 5.99, 95 % confidence intervals (CIs) 1.59-22.54, P = 0.008].
conclusionA 25(OH)D deficiency at baseline is significantly correlated with poorer clinical outcomes and more sever renal pathological features, and low levels of 25(OH)D at baseline were strongly associated with increased risk of renal progression in IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.